Blinatumomab Treatment

Phase 1Small molecule

TThe Children's Hospital of Zhejiang University School of Medicine

Blinatumomab Treatment is one of 25 small molecule programs targeting Blinatumomab. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BlinatumomabRecruiting

KidneyNot yet recruiting

BlinatumomabPhase 1

Recruiting

KidneyPhase 1

Not yet recruiting

Competition

Competitive Landscape

19 competitors in Kidney

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Approved

5 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Trimethoprim-Sulfamethoxazole

Astellas

Phase 3

1 5

Fludara

Sanofi

Phase 1

1 6

Actemra

Roche

Preclinical

2 7

Imlifidase

HHansa Biopharma AB

Phase 2

1 8

Imuran

LLegacy Health System

Preclinical

1 9

Glypressin

MMallinckrodt

Preclinical

1 10

Glucagon

XXeris Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Blinatumomab

NCT06607991

Q4 2028

Phase 1Not yet recruiting

Kidney

NCT07706205

Clinical

Trials by Indication[1]

Blinatumomab1 trial

Blinatumomab for CNI-Resistant/Intolerant SRNS in Children

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06607991·6 enrolled

Kidney1 trial

Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation

Not yet recruiting·WWest China Hospital·Phase 1·NCT07706205·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Blinatumomab Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blinatumomab Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blinatumomab Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Children's Hospital of Zhejiang University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThe Children's Hospital of Zhejiang University School of Medicine

Blinatumomab Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Blinatumomab1 trial

Kidney1 trial

References

Drug Info

Quick Facts

Related News